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1. Introduction
Vascular Smooth Muscle Cells (VSMC) are highly specialized cells whose principal functions
are contraction and regulation of blood vessel tone-diameter, blood pressure, and blood flow
distribution. In healthy adult blood vessels, these cells proliferate at a very low rate, exhibit
very low synthetic and migratory activity and express a unique repertoire of contractile
proteins, ion channels, and signalling molecules required for the cell's contractile function.
VSMC undergo significant phenotypic modulation following vascular injuries including
hypoxia, oxidative stress and mechanical injury. This phenotypic transition is mainly charac‐
terized by the loss of contractility and the acquisition of a proliferative, migratory and synthetic
phenotype. These drastic phenotypic alterations allow VSMCs to migrate from the media to
the intima of the arterial wall where they proliferate and secrete an extracellular matrix and
pro-inflammatory molecules. This phenotypic transition, also called the trans-differentiation
process, plays a critical role in pathological vascular remodellings such as atherosclerosis, post-
angioplasty restenosis, bypass vein graft failure, and cardiac allograft vasculopathy [1,2].
Hypoxia, mechanical stress and oxidative stress can induce VSMC trans-differentiation
directly or indirectly by stimulating the release of pro-inflammatory molecules and growth
factors from endothelium, macrophages, T lymphocytes or VSMC themselves. Signalling
pathways involved in VSMC trans-differentiation are diverse. Among them, the 3’-5’-cyclic
adenosine monophosphate (cAMP) signalling pathway stands out since cAMP is not only
described to play important roles both in differentiated and transdifferentiated VSMCs, but
can also have opposite effects in VSMCs with the same phenotype. Indeed, in trans-differen‐
tiated VSMCs, cAMP has dual opposite effects on migration and inflammation and stops cell
proliferation. Alternatively, in differentiated VSMCs, cAMP induces relaxation, expression of
© 2013 Glorian and Limon; licensee InTech. This is an open access article distributed under the terms of the
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contractile proteins, maintenance of a low proliferation rate and can stimulate or inhibit
apoptosis (Figure 1). The diversity of cAMP effects in VSMC (and in cells in general), is due to
the ability of this second messenger to transduce extracellular signals in a compartmentalized
manner, allowing individual stimuli to produce distinct pools of cAMP localized in discrete
subcellular regions. These pools of cAMP are produced near a subset of cAMP effectors,
themselves located near their substrates and engage specific cell responses according to the
cellular context [3]. Adenylyl cyclases (AC), phosphodiesterases (PDE) and the scaffolding
proteins A kinase anchored proteins (AKAPs) play a determinant role in cAMP compartmen‐
talization. Final cAMP effect depends on which isoforms of these proteins are expressed.
During the VSMC trans-differentiation process, important changes in the expressions of such
proteins occur, allowing a re-organization of the cAMP signalling compartmentalization,
therefore giving VSMC the ability to acquire properties specific to the trans-differentiated state.
After a presentation of the cAMP signalling pathway, this chapter discusses data demonstrat‐
ing the diversity of roles of cAMP in differentiated and transdifferentiated VSMCs.
Figure 1. Roles of cAMP (3’-5’ adenosine monophosphate) in differenciated and trans-differentiated vascular smooth
muscle cells (VSMC); AC8: adenylyl cyclase 8.
2. the c-AMP signaling pathway
2.1. Overview
The c-AMP signalling pathway begins with the release of cAMP into the cell which is mostly
initiated by the activation of G-protein coupled receptors (GPCRs) by several different
hormones and neurotransmitters. The ligand-bound GPCR catalyzes the exchange of GDP for
GTP on the α-subunit of the coupled heterotrimeric G protein, which results in the activation
of the α-subunit and its dissociation from the βγ dimer. Both the α and the βγ subunits can
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then activate or inhibit distinct intracellular signalling cascades. The αs of the Gs subtype
activates adenylyl cyclases (AC) witch catalyzes the synthesis of cAMP from ATP. Increased
levels of cAMP are translated into cellular responses by cAMP effectors. The best known is the
c-AMP dependant protein kinase A (PKA), but also include cyclic-nucleotide gated ion
channels (CNGCs) and the recently discovered Rap1-guanine nucleotide exchange factor
(Epac), three effectors known to mediate a multitude of cAMP signalling pathways. (Figure
2). The end of cAMP signalling is achieved by its decomposition into AMP catalyzed by
phosphodiesterases (PDEs) and its active efflux through transporters of the multidrug
resistance-assocuated protein (MRP) family [4,5]. One particularity of the cAMP signalling
pathway is its high degree of compartmentalization. Multiprotein complexes organize the
location of the different cAMP effectors to specific subcellular locations and allow cAMP to
propagate a plethora of cell responses in a spatio-temporal manner [3]. These multiprotein
complexes are at the foundation of cAMP compartmentalization, they involve AC, the
scaffolding proteins AKAPs and PDEs.
Figure 2. Cyclic adenosine 3’, 5’-monophosphate (cAMP) is produced from ATP by adenylyl cyclase (AC) upon activa‐
tion of Gs-protein coupled receptors. The local concentration and distribution of cAMP gradients is limited by phos‐
phodiesterases (PDE) which generate localized pools of cAMP throughout the cell. The increase in cAMP is translated
to cellular responses by the cAMP effectors protein kinase A (PKA), EPAC (exchange protein activated by cAMP) and
cyclic nucleotide -gated ion channels (CNGCs). A kinase anchored proteins (AKAPs) target cAMP effectors to distinct
cell compartments. They also intract with AC, PDE, cAMP effectors substrates and further scaffolding proteins, provid‐
ing spatial and temporal specificity of the cAMP pathway.
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2.2. Components of the c-AMP signalling pathway
2.2.1. Formation of c-AMP is regulated by adenylyl cyclases
In mammals, cAMP is synthesized from ATP by members of the Class-III AC (Adenylyl Cy‐
clase)/ADCY family (E.C 4.6.1.1)1 [6]. This class is comprised of nine trans-membrane (tm)
AC enzymes and one soluble AC (sAC). tmAC are grouped into three major sub-families:
group 1: AC1, AC3, AC8; group 2: AC2, AC4, AC7; and group 3: AC5, AC6. All nine tmAC
can be activated by GTP-bound Gαs and, with the exception of AC9, by the plant diterpen
forskolin. Nevertheless, each isoform has a specific pattern of regulation by G proteins, calci‐
um/calmodulin, and proteine kinases [7-9]. For example, differences in patterns of regula‐
tion by G proteins have been associated with isoform-specific differences in AC activation.
Whereas AC1, AC5, AC6 and AC8 are inhibited by Gαi, AC2, AC4, AC7 are not. Further‐
more, whereas Gβγ subunits inhibit isoforms AC1 and AC8, they stimulate AC2, AC4 and
AC7. GTP-bound Gαs, the activator of all tmAC, is the result of the exchange of GDP for
GTP on the α-subunit of G protein and its subsequent dissociation from the βγ dimer. This
activation can be a consequence of the binding of GPCR by several different hormones or
neurotransmitters (e.g., β-adrenergic, H2-histamine, EP2-prostaglandin, α2a adrenergic and
M2-muscarinic receptor), making GPCRs guanine nucleotide exchange factors (GEFs) for
Gα subunits. The exchange of GDP for GTP can also be mediated independently from con‐
ventional GPCR/G protein signalling. This way involves entities called “non-GPCR GEFs”,
such as the recently identified cholinesterase -8a (Ric8a), a cytosolic protein reported to bind
to and act as a GEF for numerous Gα in mammalian cells [10]. Signal de-activation is ach‐
ieved by Gα-mediated GTP hydrolysis (endogenous GTPase activity) allowing return of the
Gα subunit to the inactive GDP-bound and its association with Gβγ dimer to form a Gα βγ-
heterotrimeric complex.
Beyond their synthase activity, ACs can function as scaffolds, and therefore contribute to the
cAMP signalling compartmentalization. Indeed, several works have shown that specific AC
isoforms have the capacity to interact with several proteins/enzymes on their N-terminus
allowing an isoform selective coupling with specific downstream signalling cascades [11,12].
AC isoforms are themselves confined in several structural specific cellular compartments. The
best characterized is their association with caveolar, lipid-rafts and the anchoring proteins
AKAP [13,14]. Selective adenylyl cyclase isoform localization, regulation and coupling with
specific downstream targets provide adenylyl cyclase isoform-selective patterns of signalling,
that links specific AC isoforms to distinct cell processes [15,16]. For example, alteration of the
AC population expressed in DDT1-MF2 cells (derived from hamster vas deferens smooth
muscle) changes the processing of stimulatory and inhibitory input [17] and differential
expression of AC isoforms in two VSMC models account for opposite effect of isoprenaline on
cAMP production [18].
1 Adenylyl cyclases (ACs) are currently grouped in six classes based on their primary amino acid sequences. Class I ACs
have been found exclusively in γ -proteobacteria. Class II ACs are toxins secreted by Bacillus anthracis, Bordetella
pertussis and Pseudomonas aeruginosa. Only few members of class IV, V and VI ACs have been described to date and
consists in bacterial enzymes. Class III ACs is universal. Class III ACs is found in metazoa, protozoa, fungi, eubacteria,
some archaebacteria and certain green algae. Neither class III ACs nor any other type of AC has ever been conclusively
identified in higher plants (Embryophyta).
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Differentiated  VSMC  have  been  shown  to  express  different  isoforms  of  AC  [18,19].
AC3-5-6 are clearly the most highly expressed isoenzymes in VSMCs, while Type 8 AC
(AC8) is undetectable in differentiated VSMCs and is strongly induced in trans-differenti‐
ated VSMC [20,21].
2.2.2. Degradation of cAMP is regulated by the cyclic nucleotide phosphodiesterases
Phosphodiesterases (PDE) comprise a large superfamily of enzymes; 11 families (PDE1-
PDE11) have been characterized on the basis of their amino acid sequences, substrate specif‐
icity, allosteric regulatory characteristics and pharmacological properties [22,23]. In total, the
superfamily of PDEs encompasses 25 genes in mammals giving rise to 200 reported distinct
gene products corresponding to different splice variants that are often expressed in a tissue-
specific manner. The substrate specificity of PDEs includes cAMP-specific, cGMP specific, and
dual-specific PDE. PDE 4-7-8 are highly specific for the hydroysis of cAMP, PDE5, 6, 9 are
cGMP specific and PDE1, -2, -3, -10, -11 hydrolyse both cAMP and cGMP. There are four major
PDE families found in VSMCs: PDE1, PDE3, and PDE4 PDE5 [24]. PDE3 and PDE4 have been
shown to account for the majority of cAMP hydrolysis, whereas PDE1 and PDE5 are mainly
responsible for cGMP-hydrolysis [25,26]. PDE1A and -1B, are expressed in differentiated
VSMC. PDE1A has the particularity to be localized in different cell compartments according
to the VSMC phenotype; it is predominantly cytoplasmic in medial contractile VSMC and
becomes nuclear in neointimal synthetic VSMC [27]. PDE1C is specifically induced in trans-
differentiated VSMC [28]. PDE3A, the main isoform expressed in arterial tissue, platelets and
cardiac tissue is found is VSMCs as well as PDE3B. The largest PDE family to date, the cAMP
specific PDE4 family, is expressed in numerous tissues, notably in vascular tissue. Four genes
(PDE4A/B/C/D) encode over 20 distinct PDE4 isoforms as a result of mRNA splicing and the
use of distinct promoters [29]. It was reported that two PDE4 “long forms”, PDE4D3 and
PDE4D5 are expressed in rat and human VSMC [30,31] and that the two “short forms” PDE4D1
and PDE4D2 are specifically expressed in trans-differentiated VSMC [32]. PDE5A is the major
cGMP hydrolyzing PDE expressed in arterial tissues[33,34].
2.2.3. Effectors of cAMP action
2.2.3.1. PKA
The first intracellular target of cAMP identified is the well characterized PKA holoenzyme.
cAMP-PKA-mediated signalling is known to affect numerous intracellular targets in response
to a wide variety of molecular signals. Numerous studies over the past 40 years have identified
hundreds of PKA substrates in the plasma membrane, nucleus, and cytoplasm of cells. The
PKA holoenzyme is a tetramere consisting of two catalytic subunits (C) that are maintained in
an inactive conformation by a regulatory (R) subunit dimer [35]. Binding of two cAMP
molecules on each R subunit leads to a conformational change and dissociation of two
catalycally active C monomers, which phosphorylate serine and threonine residues on specific
substrate proteins. Molecular cloning identified 4 R subunits and 4 C subunits called respec‐
tively RIα, RIβ, RIIα, RΙΙβ, Cα, Cβ, Cγ, and PRKX (the human X chromosome-encoded protein
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kinase X, a cAMP dependent kinase that forms a catalytically inactive holoenzyme only with
the RI subunit). The R subunits exhibit different cAMP binding affinities and can form both
homo and heterodimers leading to a large number of combinations. The subcellular localiza‐
tion of PKA is determined by PKA binding to A kinase ankoring proteins, AKAPs. AKAPs act
as scaffolds which give PKA access to substrates localized in specific compartments within the
cell and participate to cAMP signalling compartmentalization as depicted below [36,37].
2.2.3.2. Epac family
Epac proteins are the most recent addition to the group of cAMP signalling effectors. Their
discovery explains various effects of cAMP that could not be attributed to the established
targets PKA and CNGs. Epac was identified in a database screen conducted to explain the
independent activation of the small G protein Rap by cAMP [38]. At the same time, a screen
for proteins containing cyclic-nucleotide-binding domains revealed the presence of two
isoforms of Epac, Epac1 and Epac2 [39]. Epac proteins function as guanine nucleotide exchange
factors (GEFs) both for Rap1 and Rap2. Rap1 and rap2 proteins belong to the Ras family of
small G proteins, which cycle between an inactive GDP-bound state and an active GTP-bound
state. The GTP-bound Rap mediates signalling by associating with and activating effector
proteins. GEFs catalyze the exchange of GDP for GTP and thereby the activation of the small
G protein (Figure 3). Herein, Epac1 and Epac2 proteins are also called cAMP-GEF I and II
respectively. Their subcellular localizations are determined, like PKA, by binding to AKAPs.
Epac1 and Epac2 are present in most tissues, though with different expression levels. Epac1 is
highly abundant in blood vessels, kidney, adipose tissue, central nervous system, ovary and
uterus, whereas Epac2 is mostly expressed in the central nervous system, adrenal gland, and
pancreas. Epac proteins are implicated in many cAMP-regulated processes such as insulin
secretion, cardiac contraction, vascular permeability, cell migration, neurotransmitter release
and immunity [40,41].
2.2.3.3. CNG famly
Cyclic nucleotide-gated (CNG) channels are non-selective cation channels first identified in
retinal photoreceptors and olfactory sensory neurons. They are opened by the direct binding
of cAMP and cGMP. Although their activity shows very little voltage dependence, CNG
channels belong to the super-family of voltage-gated ion channels.
CNG channels consists in heterotetrameric complexes resulting from the association of two or
three subunits. Six different genes encoding CNG channels, four A subunits (A1 to A4) and
two B subunits (B1 and B3), give rise to different channels. Their activity is modulated, at least
in part, by Ca2+/calmodulin and by phosphorylation. The role of CNG channels has been
established in retinal photoreceptors and in olfactory sensory neurons. Mutations in CNG
channel genes give rise to retinal degeneration and color blindness [42].
CNG channels are widely expressed in vascular tissues across species and vascular beds
[43,44]. Specifically, CNGA1 was found to be very expressed in the endothelium layer and,
with a much lower extent, in VSMC [44]. In contrast, strong expression of CNGA2 has been
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found in both the endothelium and media of human arteries [43]. Functionally, CNG channels
play an important role in endothelium dependent vascular dilatation to a number of cAMP-
elevating agents including adenosine, adrenaline and ATP [45-47]. Concerning the function of
CNG in differentiated VSMC, to our knowledge, only one report demonstrates that CNG
contributes to thromboxaneA2-induced contraction of rat small mesenteric arteries[48].
Figure 3. The Rap1 GTPases cycle between a GTP-bound (active state) and GDP- bound (inactive state). Cycling be‐
tween the active and inactive states is facilitated by guanine nucleotide exchange factors (GEFs) that release GDP and
allow binding of GTP, as well as GTPase activation proteins (GAPs) wich accelerate GTP hydrolysis.
2.3. ACs, PDEs and AKAPs are essential to cAMP signaling
compartimentalization
The idea of compartimentalized pools of cAMP originated in 1979 when Brunton et al. showed
that while both the β-adrenergic receptor agonist isoprotrenol and prostaglandin E1 increased
cAMP concentration in perfused rat hearts, only isoproterenol increased glycogen metabolism
and phosphorylation of troponin [49]. These results illustrated the fact that different hormones
may act through the same messenger to generate different pools of cAMP and mediate distinct
physiological responses. An increasing number of results support now the existence of distinct
cAMP microdomains that control cAMP signalling. ACs, PDEs and the scaffolding proteins
AKAPs are at the foundation of this cAMP signalling compartmentalization [50,51]. As
mentioned, -ACs can orchestrate their own microenvironment by recruiting a variety of
signalling and scaffolding molecules, - PDEs mediate local cAMP degradation and literally
sculpt gradients of cAMP surrounding specific signalling complexes and therefore regulate
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the availability of cAMP/cGMP to their effectors –AKAPs dynamically assemble the three
different cAMP effectors to control the cellular actions of cAMP [37]. As their name implies,
AKAPs were originally described to target PKA to distinct subcellular locations and confine
activation to only a subset of potential targets. In reality, these proteins have the ability to form
complexes with other signalling molecules including Epac proteins, protein kinases, phos‐
phatases, phosphodiesterases, AC, as well as GPCR and ion channels. AKAPs are localized to
numerous cellular sites, including the plasma membrane, Golgi, centrosome, nucleus,
mitchondria and cytosol. The first AKAP to be characterized was microtubule associated
protein-2 (MAP2), initially identified because of it co-purified with RII from brain extract [52].
The AKAP family has grown and includes more than 50 structurally diverse, but functionally
similar members. Despite their diversity, AKAP orthologues have been identified in a range
of species, including yeast, nematodes, mice and humans. All AKAPs share common proper‐
ties: 1) they contain a PKA-anchoring domain 2) compartmentalization of individual AKAP-
PKA units occur through specialized targeting domains that are present on each anchoring
protein 3) they have the ability to form complexes with other signalling molecules including
protein kinases, phosphatases, phosphodiesterases, AC, as well as GPCR and ion channels 4)
AKAPs are recruited into much larger multiprotein complexes through the interactions with
other adaptator molecules such as PDZ and SH3 domain containing proteins. These four
properties of AKAPs allow these proteins to integrate multiple signalling pathways, allowing
the convergence of signals to a common target [36,37].
3. Roles of cAMP in differentiated VSMCs
3.1. cAMP induces relaxation of differentiated VMCs
Elevation of intracellular cAMP after activation of Gs coupled receptors by vasorelaxing
hormones such as adrenaline, noradrenaline and the endothelium-derived prostaglandine I2
(PGI2) induces a rapid and efficient relaxation of mature differentiated SMCs [53]. Moreover,
the cAMP elevating agent forskolin induces a relaxant effect in VSMCs in vivo which is
potentiated by inhibitors of PDE3 and PDE4, the two main PDE isoforms expressed in VSMCs
[25,26,30] [54]. In SMCs, cAMP contributes to muscle relaxation through two different
mechanisms; one through the stimulation of the Ca pump at the sarcolemmal membrane (Ca
extrusion) and sarcoplasmic reticulum (Ca accumulation), and the other through the de-
phosphorylation of myosin light chain kinase (MLCK). De-phosphorylation of MLCK is
accomplished by the myosin light chain phosphatase (MLCP) which is well known to be
activated upon phoshorylation by the cAMP target PKA or the cGMP dependent protein kinase
G (PKG) [55,56]. Conversely, when phosphorylated by Rho-associated kinase (ROCK) or PKC,
MLCP activity is inhibited, resulting in contraction. A new mechanism of cAMP-mediated
relaxation has been recently described in airway and aortic smooth muscle cells involving
Epac, the last cAMP effector identified. Activation of Epac by an Epac selective cAMP analog
in pre-contracted aortic smooth muscle cells and airway smooth muscle cells results in the
down regulation of RhoA activity and in the increase of Rap1 or Rac1 activities, leading to cell
relaxation [57,58]. cAMP pools involved in SMC relaxation may be mainly generated by the
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type 6 adenylyl cyclase (AC6). Indeed, overexpression of only AC6 (and not AC5, AC2, or
AC1) in primary aortic VSMCs enhances smooth muscle relaxation [59]. Furthemore, a recent
study using selective short interfering RNA sequences reveals that AC6 is the predominant
isoenzyme involved in vasodilator-mediated cAMP accumulation in aortic VSMCs, account‐
ing for 60% of the total response to β-adrenoceptor (β-AR) stimulation [60].
3.2. cAMP maintains a low rate of proliferation in differentiated VSMC
A cause to effect relationship between the decreased expression of some specific components
of the cAMP signalling and proliferative capacity of VSMC has been demonstrated. Inversely,
emergence of PDEs in trans-differentiated VSMC allows them to proliferate.
3.2.1. Role of CREB
The cAMP Response Element Binding Protein (CREB) is a transcription factor, well known to
be phosphorylated and activated by PKA. CREB expression has been shown to be dramatically
decreased in cultured trans-differentiated VSMCs and in the media of numerous rodent and
porcine models of vascular diseases. Depletion of this transcription factor in vivo elicits changes
consistent with those observed in SMCs from pathologically remodelled arteries whereas
forced depletion of CREB with small interfering RNA in aortic SMCs is sufficient to induce
their proliferation, hypertrophy, migration, de-differentiation, and ECM production. Furthe‐
more, CREB is inactivated in VSMCs by several proliferative stimuli and overexpression of
wild type or constitutively active CREB, in primary cultures of SMC arrests cell cycle progres‐
sion induced by these stimuli [61-66]. Additionally, Transforming growth factor beta and
thiazolidinediones activate CREB to oppose to aortic SMC proliferation induced by growth
factors [62,67]. Nevertheless, some apparent contradictory studies show that CREB is involved
in VSMC proliferation induced by ATP and thrombin [68,69].
3.2.2. Role of CREB AKAP12β and AKAP5
AKAP12β, a member of the AKAP family, is markedly decreased in human and rodent
vascular lesions. Overexpression of AKAP12 β attenuates serum-induced SMC growth in vitro
and a causal relationship exists between the induction of the expression of this protein and the
inhibition of serum-induced VSMC proliferation by all trans retinoic acid [70]. An other AKAP
shown to repress VSMC growth is AKAP5 (AKAP79/AKAP75/AKAP150 in human, bovine,
rat respectively) since over-expression of this protein inhibits serum-induced VSMC prolifer‐
ation and local delivery of AKAP5 to balloon-injured vessels wall reduced the extent of
neointimal burden [71].
3.2.3. Role of PDE1-C
PDE1C, a PDE isoform hydrolyzing both cAMP and cGMP, is expressed in proliferating
human VSMCs but is absent in quiescent cells. In vivo, PDE1C is expressed in human foetal
aortas containing proliferating SMCs, but not in newborn aortas in which SMC proliferation
has ceased. Moreover, a causal relationship has been established between the emergence of
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PDE1-c in VSMCs and their capacity to proliferate, since specific inhibition of PDE1C in SMCs
isolated from normal aorta or from lesions of atherosclerosis results in suppression of SMC
proliferation [72].
3.3. Others roles of cAMP in differentiated VSMC
3.3.1. cAMP maintains the contractile phenotype of differentiated VSMCs
As mentioned above, CREB depletion elicits changes consistent with those observed in SMCs
from pathologically remodelled arteries in vivo. These changes include modifications in the
expression of SMC markers and contractile factors such as SM myosin, and strongly suggest
that cAMP is important in maintaining the contractile phenotype of differentiated VSMCs [64].
The role of CREB in the maintenance of the contractile phenotype is reinforced by a recent
publication showing that cAMP elevation by cilostazol, a potent type 3 phosphodiesterase
inhibitor, promotes VSMC differentiation through CREB [73].
3.3.2. cAMP has dual opposite effects on apoptosis of differentiated VSMCs
Some studies demonstrate that cAMP is pro-apoptotic in SMCs whereas others present cAMP
as an anti-apoptotic factor in these cells. The opposite effect of cAMP on apoptosis in the same
type cell can be explained by the compartmentalization of cAMP signalling since these studies
use different ways to elevate intracellular cAMP. Some studies use cAMP elevating agents,
whereas others use hormones such as prostacyclin. In aortic VSMC, Torella et al. show that
cAMP analogs inhibits apoptosis through Ser83 phosphorylation of p85αPI3K [77]. Addition‐
ally, in the same model, the AC activator forskolin reduces apoptosis in serum-deprived rat
aortic VSMC at a site upstream of caspase 3 via activation of PKA [78]. In line with these studies,
inhibition of CREB function in aortic VSMC induces apoptosis of rat aortic VSMC, possibly
through downregulation of bcl2 expression [79]. Adversely, cAMP elevation in response to
prostacyclin induces apoptosis in rat aortic VSMC through the inhibition of extracellular
signal-regulated kinase activity [80].
4. Roles of cAMP in trans-differentiated VSMCs
4.1. cAMP inhibits proliferation of trans-differentiated VMCs
cAMP is well known to diminish cell growth and to promote cell-differentiation in general, it
can even be antagonistic to the effect of growth factors [81]. The first clue that cAMP might
have a role in controlling growth of cultured cells emerged from two studies. Burk observed
that two drug inhibitors of cAMP phosphodiesterase activity, caffeine and theophylline,
slowed the growth of normal and transformed baby hamster kidney (BHK) cells [82]. At the
same time, Ryan and Heidrick reported that cAMP itself inhibited the growth of Hela cells [83].
The first demonstration that cAMP inhibits proliferation of VSMCs was done by Southgate
and Newby showing the inhibitory effect of 8-Br-CAMP on serum-induced proliferation of
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rabbit aortic smooth muscle cells [84]. This inhibitory effect of cAMP on VSMC growth was
confirmed in vitro [85,86] and in vivo by Indolfi et al., demonstrating that local or oral admin‐
istration of cell-permeable, cyclic AMP analog, 8-Br-cAMP and non-selective phosphodiester‐
ase-inhibitor drugs to rats markedly inhibits neo-intimal formation after balloon injury in
vivo and/or in vitro in SMC [87,88]. Selective inhibitors of PDE3A and PDE4D, the two main
PDE isoforms expressed in VSMCs that account for cAMP hydrolysis [25,26,30] were also
shown to inhibit proliferation of trans-differentiated VSMCs. PDE3 and PDE4 inhibitors
markedly potentiate both the anti-proliferative effect and the increase in cAMP caused by
forskolin and PGI2 and significantly inhibit PDGF-induced VSMC proliferation and migration
[89,90]. [Of note, PDE4D is the first gene that has been linked to common forms of stroke such
as cardiogenic and carotid strokes [91]. Moreover, PDE3 inhibitors administred orally are able
to inhibit VSMC proliferation in a model of photochemically-induced vascular injury (Kondo
et al., Atherosclerosis, 1999), and a recent publication clearly demonstrates that PDE3A
depletion in vitro and in vivo inhibits mitogen-induced VSMC proliferation [61]. The AC
isoform that could play a role in cAMP-mediated inhibition of VSMC growth is the type 3
adenylyl cyclase (AC3) since Wong et al. demonstrated that this protein mediates the inhibitory
effect of prostaglandin E2 (PGE2) on basal and PDGF-BB-induced proliferation in murine and
human arterial VSMC [51]. Various molecular mechanisms have been proposed to explain
AMP-mediated inhibition of VSMCs. Such mechanisms include subsequent suppression of
growth factor-mediated activation of mitogenic protein kinases in VSMCs. Indeed, cAMP can
oppose to the mitogen-activated protein (MAP) kinases ERK1/2 [61,92], to JNK1 [93] as well
as to the phosphatidylinositol 3-kinase effector S6K1 [92]. In addition, cAMP can regulate gene/
protein expression which may contribute to its anti-proliferative action. For example, cAMP
elevating agents restore expression of p53-p21 in response to PDGF [61,94], prevents serum-
induced expression of cyclin-dependent kinases [95], inhibits basal and glucose-induced
VSMC growth by a down-regulation of the transcription factor E2F [25] and can reduce the
serum-induced expression of the S-Phase kinase-Associated Protein 2 (Skp2), an important
factor for cell cycle progression in VSMCs [96]. Furthermore, prostacyclin-induced cAMP
intracellular elevation inhibits the proliferation of arterial smooth muscle cells by inhibiting
the smad1/5 driven expression of Id1 (inhibitor of DNA binding protein) gene [97]. Some of
the genic effects of cAMP in VSMCs may be mediated by CREB since this transcription factor
has been demonstrated to inhibit the expression of a number of cell-cycle and mitogenic genes
in trans-differentiated VSMCs as well as genes encoding growth factors, growth factor
receptors, and cytokines [61,64,98]. The cAMP effectors PKA and Epac both are involved in
cAMP VSMC growth inhibition. Indeed, PKA inhibitors have been shown to reverse or, at
least, inhibit the effect of cAMP elevating agents on VSMC proliferation [71,77,87,88,99].
Concerning the involvement of Epac in VSMC proliferation, Mayer and collaborators and
Hewer and collaborators respectively demonstrated that Epac is involved in the adenosine-
mediated decrease of cell proliferation in human VSMCs and acts synergically with PKA to
mediate cAMP-dependent cell-cycle arrest and associated induction of a stellate- morphology
in VSMCs [100,101].
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4.2. cAMP has dual opposite effects on migration of trans- differentiated VMCs
4.2.1. cAMP inhibit migration of trans-differentiated VSMCs
A growing body of evidence emerged in the beginning of the 1990’s implicating cAMP in the
inhibition of trans-differentiated VSMC migration. These studies, using analogs of cAMP,
activators of ACs and cAMP raising agents in VSMCs, have demonstrated that an increase in
cAMP positively correlates with the inhibition of VSMC migration. Indeed, raising the
intracellular concentration of cAMP either with dopamine, acting throught D1 receptors,
adrenomedullin, or forskolin, inhibited migration of VSMCs stimulated with PDGF or serum
[102-104]. Studies in rat aortic SMCs suggest that vasoactive agents that elevate intracellular
cAMP inhibit cell movement by disassembling actin stress fibers of the cytoskeleton [105,106].
Furthermore, downregulation of PKA abrogates inhibition of VSMC chemotaxis by forskolin
[89]. The inhibitory effect of cAMP on VSMC migration is re-inforced by the fact that inhibiting
all together PDE3 and PDE4D, the two main PDE isoforms expressed in VSMCs that account
for cAMP hydrolysis in VSMC [26,30,107] markedly potentiated both the anti-migratory effect
and the increase in cAMP caused by forskolin and significantly inhibited PDGF-induced
VSMC proliferation and migration [90,108,109]. In addition, Newman et al demonstrated that
forskolin inhibits TNFα-induced interleukin 6 expression and migration in human vascular
smooth muscle cells [110]. This effect could involve the transcription factor CREB since PDGF-
induced migration was decreased by active CREB and augmented with dominant negative
CREB [66,95] ; In addition, a negative correlation has been described between the CREB level
and the PDGF-activated SMC migration [64]. Nonetheless, the role of CREB in SMC migration
remains unclear since CREB has been demonstrated to be involved in UTP, arachidonic acid
and TNF alpha-induced SMC migration of VSMCs [111,112]. Moreover, recent studies show
that oxidized and non-oxidized fatty acids induce SMC motility through this transcription
factor [113,114].
4.2.2. A specific endogenous pool of cAMP induces migration of trans- differentiated VSMCs
By demonstrating that differential  expression of ACs isoforms in two VSMC models ac‐
count for opposite effects of isoprenaline on cAMP production in VSMC, Webb and co-
workers suggested for the first time that changes of AC isoform(s) expression in VSMCs
could account for the manifestation of vascular diseases [18].  In line with this study, Li‐
mon’s  group recently  demonstrated that  the  emergence of  the  calcium/calmodulin posi‐
tively regulated AC isoform 8 (AC8) in trans-differentiated VSMCs is involved in VSMC
migration. Type 8 AC is barely undetectable in differentiated VSMCs and is strongly in‐
duced in trans-differentiated VSMCs. A causal relationship between AC8 apparition and
the  migratory  capacities  of  VSMCs has  been  established.  Indeed,  authors  show that  10
days after  balloon angioplasty2,  rat  carotid artery displayed high AC8 immuno-labelling
only in the neo-intima and was no longer detectable when it  was analyzed after the re-
endothelization  phenomenon  during  which  VSMC migration/proliferation  halted.  More‐
2 Balloon angioplasty in rat carotid artery serves as an in vivo model of VSMC migration and proliferation.
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over,  the  forced  expression  of  AC8  in  primary  rat  VSMC  cultures  triggered  the  re-
colonization  of  a  wounded  zone,  whereas  blocking  it  in  IL-1β−cells  stopped  the  IL-1β-
induced  migration  [21]  This  finding  was  extending  in  vivo,  on  human  samples,  where
only the neo-intimal VSMCs a high level of AC8. Of note, AC8 is well known for its role
in  stress  adaptation,  mood disorders  and  opiate  dependence  [115].  The  involvement  of
this  enzyme in  VSMC trans-differentiation was  therefore  unexpected.  Molecular  mecha‐
nisms  underlying  AC8-mediated  VSMC  migration  does  not  involve  PKA  but  could  in‐
volve  Epac1  since  it  has  been  shown  that  Epac  1  expression  is  upregulated  in  the
neointima  after  vascular  injury  of  mouse  arteries  and  induces  VSMC  migration.  More‐
over Rap1, one of the described targets of Epac, is well known for its involvement in cell
migration [116].
4.3. cAMP has dual opposite effects on inflammation of trans-differentiated VMCs
A study from Adkins and coll. demonstrate that the elevation of intracellular cAMP by
rapamycin inhibits the secretion of the pro-inflammatory molecule Tumor Necrosis Factor
alpha (TNF-α) in lipopolyssacharide treated VSMCs from human saphenous vein segments
[110]. Adversely, Clement and collaborators suggest that the production of cAMP specifically
by AC8 is involved in the potentiator effect of prostaglandin E2 (PGE2) on the secretion of
phospholipase A2 (sPLA2), a marker of inflammation, in response to interleukine 1 β (IL1β)
in primary cultures of rat aortic smooth muscle cells [20]. In details, authors show that PGE2
i) induces the transition of CMLV towards a trans-differentiated/ inflammatory state through
the activation of the subtype 4 Gs-linked PGE2 receptor EP4, ii) acts in synergy with IL1β to
potentiate the secretion of phospholipase A2 and the disorganization of the alpha actin
cytoskeleton. This potentiator effect is the result of a simultaneous activation of PGE2 receptors
EP4 and EP3: in differentiated VSMC, EP3 receptors inhibit cyclase activity induced by EP4
and become activator of this activity in trans-differentiated VSMC. This switch of regulation
is the result of the emergence of AC8 in IL1β−treated VSMC.
4.4. cAMP inhibits collagen synthesis of trans-differentiated VSMCs
Synthetic VSMCs, in the atherosclerotic and neointimal lesions, produce an abundant exra-
cellular matrix (ECM), rich in type I collagen (collagen I). This ECM plays an important role
in vessel wall thickening and in the occlusion of the vessel lumen. In addition, collagen I in
vascular lesions may also regulate VSMC proliferation/migration, platelet circulation, mono‐
cyte activation, lipid accumulation, calcification, and plaque stability [74]. cAMP elevating
agents have been shown to inhibit collagen I synthesis induced by fetal calf serum- and TGF-
β [75]. Emergence of PDE1-c in trans-differentiated SMCs from rat aortic and human saphe‐
nous vein explants opposes the inhibitory effect of cAMP on collagen 1 synthesis, and accounts,
at least in part, for the increase of collagen 1 expression in trans-differentiated VSMCs. The
use of specific pharmacological inhibitors and si-RNA reveal that the cAMP-mediated
inhibitory effect on collagen 1 synthesis involves cyclic nucleotide gated channels but not PKA,
nor Epac [76].




Depending on the relative abundance and localization of the components of the cAMP signal‐
ling pathways, cAMP effects on VSMC vary in differentiated and trans-differentiated VSMCs
(Figure 4). Because trans-differentiated VSMCs play a crucial role in atherosclerosis and are
solely  responsible  for  post-angioplasty  restenosis,  understanding  molecular  mechanisms
leading to VSMC trans-differentiation is crucial to develop novel therapeutic strategies. Re‐
ducing post-angioplasty restenosis which affects 20-25% of patients treated with bare metal
stents, is one of the major challenges in cardiovascular medicine. At the beginning of 2000’s,
the apparition of stents locally releasing anti-proliferative drugs (ie drug-eluting stents (DES),
have significantly changed interventional cardiology, due to their remarkable ability to reduce
restenosis compared to bare metal stents, However, their overwhelming success has quickly
decreased since is limited due to an increased risk of late stent thrombosis. Poor re-endothelial‐
ization remains the major important pathologic predictor of late stent thrombosis [117], there‐
fore, it has been suggested that DES should ideally have a selective anti-migratory and/or
proliferative effect on VSMCs, without affecting, or, even better, promoting re-endothelializa‐
tion [77,118]. Identifying the specific components of the cAMP pathway specifically involved
in VSMC trans-differentiation may be a novel concept for the development of new drugs for
DES, therefore improving the treatment of pathological vascular remodellings.
Figure 4. Expression of cAMP components in differentiated and trans-differentiated VSMC and consequences on
VSMC functions. AC adenylyl cyclase; AKAP A-kinase anchoring proteins; Epac exchange proteins directly activated by
cAMP; CREB cAMP response element binding protein; PDE phosphodiesterases.
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